A review of imlifidase in solid organ transplantation

Author:
Publisher website
Google Scholar
Abstract
Introduction: Sensitization to human leukocyte antigens has long posed an obstacle to organ transplantation. With desensitization protocol refinement, new drug development, and organ allocation policy changes, access to transplant for sensitized patients has never been greater. Yet in spite of these advances the problem of donor specific antibody remains incompletely solved, and many patients remain poorly served by the therapies that do exist. Area covered: Imlifidase is a new drug with a mechanism of action that enables it to transiently yet efficiently eliminate donor specific antibody over a much more rapid time course than any heretofore existing therapy. This unique property suggests that imlifidase may have far reaching potential for patients in whom donor specific antibodies may preclude successful transplantation. Below follows a review of the clinical experience with imlifidase to date as well as a discussion the transplant applications that eagerly await the availability of this novel agent. Expert opinion: Imlifidase is a first-in-class pharmaceutical agent that safely and efficiently cleaves IgG, and holds promise to be a game changer for sensitized patients in need of lifesaving organ transplants.
Funding Information
  • not funded

This publication has 54 references indexed in Scilit: